Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
MNPR 
Monopar Therapeutics Inc (MNPR)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
12/03/2025: MNPR (3-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Number of Analysts
5 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $111.77
1 Year Target Price $111.77
| 2 | Strong Buy |
| 2 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 544.46% | Avg. Invested days 55 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  5.0 |
| Profits based on simulation | Last Close 12/03/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 507.48M USD | Price to earnings Ratio - | 1Y Target Price 111.77 |
Price to earnings Ratio - | 1Y Target Price 111.77 | ||
Volume (30-day avg) 5 | Beta 1.47 | 52 Weeks Range 20.61 - 105.00 | Updated Date 12/2/2025 |
52 Weeks Range 20.61 - 105.00 | Updated Date 12/2/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -3.96 |
Earnings Date
Report Date 2025-11-10 | When - | Estimate -0.3989 | Actual -0.48 |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -17.99% | Return on Equity (TTM) -26.54% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 432300183 | Price to Sales(TTM) - |
Enterprise Value 432300183 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -2.42 | Shares Outstanding 6682584 | Shares Floating 3916529 |
Shares Outstanding 6682584 | Shares Floating 3916529 | ||
Percent Insiders 23.76 | Percent Institutions 65.01 |
Upturn AI SWOT
Monopar Therapeutics Inc
Company Overview
History and Background
Monopar Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to improve patient outcomes in oncology and other serious diseases. Founded in 2014, it has focused on acquiring and developing promising drug candidates.
Core Business Areas
- Oncology: Development of innovative cancer therapies.
- Autoimmune: Research and development of therapies for autoimmune diseases.
Leadership and Structure
Chandler D. Robinson is the CEO. The company has a typical structure of a publicly traded biopharmaceutical company with a board of directors and various management teams overseeing research, development, and operations.
Top Products and Market Share
Key Offerings
- Validiveu00ae: A mucositis treatment; rights reverted to the licensor. Competitors include Amgen (BLINCYTO), Helsinn Healthcare (ALOXI), and numerous supportive care strategies like mouthwashes.
- camsirubicin: An investigational drug candidate being evaluated for the treatment of advanced soft tissue sarcoma (ASTS). Its competitors would include established chemotherapies and targeted therapies such as doxorubicin and pazopanib. No revenue yet.
Market Dynamics
Industry Overview
The biopharmaceutical industry is highly competitive, research-intensive, and subject to strict regulatory oversight. It involves the discovery, development, and commercialization of pharmaceutical products. Oncology and Autoimmune diseases are areas of large unmet need and substantial market opportunity.
Positioning
Monopar is a clinical-stage company aiming to develop differentiated therapies. Their competitive advantage lies in novel mechanisms of action and improved formulations.
Total Addressable Market (TAM)
The TAM for oncology and autoimmune therapies is vast, estimated in the hundreds of billions of dollars annually. Monopar is targeting specific niches within these markets with high unmet needs, allowing them to potentially capture significant value.
Upturn SWOT Analysis
Strengths
- Proprietary drug candidates
- Experienced management team
- Focus on unmet medical needs
Weaknesses
- Limited financial resources
- Dependence on clinical trial success
- No currently marketed products
Opportunities
- Positive clinical trial results
- Strategic partnerships
- Acquisition by larger pharmaceutical company
Threats
- Clinical trial failures
- Regulatory hurdles
- Competition from established pharmaceutical companies
Competitors and Market Share
Key Competitors
- JNJ
- MRK
- BMY
Competitive Landscape
Monopar faces significant competition from larger, established pharmaceutical companies. Its success depends on its ability to develop and commercialize differentiated therapies that address unmet medical needs.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is limited due to the company's stage of development, with limited revenue generation to date.
Future Projections: Future projections depend on the success of clinical trials. Analyst estimates are not available without a dedicated data feed.
Recent Initiatives: Recent initiatives include progressing camsirubicin through clinical trials and exploring other therapeutic candidates.
Summary
Monopar Therapeutics is a clinical-stage biopharmaceutical company with promising drug candidates, but it faces significant challenges. The company's success hinges on positive clinical trial outcomes and effective strategic partnerships. Its limited financial resources and competition from larger players present considerable risks. Monopar needs to secure additional funding and achieve clinical milestones to enhance its value proposition.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Industry reports
Disclaimers:
This analysis is based on publicly available information and is not financial advice. Market share data is estimated and may not be precise. Real-time data was not used.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Monopar Therapeutics Inc
Exchange NASDAQ | Headquaters Wilmette, IL, United States | ||
IPO Launch date 2019-12-19 | Co-Founder, CEO, President & Director Dr. Chandler D. Robinson M.B.A., M.D., M.Sc., MBA, MSc | ||
Sector Healthcare | Industry Biotechnology | Full time employees 14 | Website https://www.monopartx.com |
Full time employees 14 | Website https://www.monopartx.com | ||
Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. The company develops ALXN1840, a late-stage, investigational once-daily and oral medicine; MNPR-101, a proprietary humanized monoclonal antibody that is conjugated with different radioisotopes for the treatment of advanced solid tumors expressing urokinase plasminogen activator receptor; and MNPR-101-Zr, a clinical-stage radiodiagnostic imaging agent comprised of MNPR-101 conjugated to zirconium-89. It develops MNPR-101-Lu, a late-preclinical stage radiotherapeutic comprised of MNPR-101 conjugated to actinium-225. The company has collaborations NorthStar to develop radio-immuno-therapeutics targeting severe COVID-19. The company was founded in 2014 and is headquartered in Wilmette, Illinois.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.